Open AccessResistant arterial hypertension: the search of new approaches to antihypertensive drug therapy
Author(s) -
О. Б. Кузьмин,
Л. Н. Ландарь,
С. В. Сердюк,
В. В. Белянин,
Л М Тулина
Publication year - 2021
Publication title -
arterialʹnaâ gipertenziâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-8524
pISSN - 1607-419X
DOI - 10.18705/1607-419x-2021-27-3-309-317
Subject(s) - medicine , blood pressure , spironolactone , doxazosin , drug , antihypertensive drug , pharmacotherapy , pharmacology , adverse effect , bisoprolol , population , intensive care medicine , cardiology , heart failure , environmental health
Improving the effectiveness of drug therapy and reducing the risk of adverse cardiovascular and renal outcomes in patients with resistant hypertension (HTN) remains an unsolved problem of cardiology. The results of the PATHWAY-2, PATHWAY-3 and ReHOT studies have shown the clinical efcacy of spironolactone, amiloride and, to a lesser extent, the antiadrenergic drugs clonidine, bisoprolol and doxazosin in improving blood pressure (BP) control in this patient population. However, the inclusion of spironolactone and other known drugs in antihypertensive therapy does not ensure the achievement of target BP level in a signicant proportion of these patients. The review presents the results of clinical studies of new approaches aimed at increasing the effectiveness of drug therapy in resistant HTN including sodium-glucose cotransporter type 2 inhibitors, brain aminopeptidase A inhibitors, and new antagonists of endothelin receptors.